Tedizolid phosphate is under clinical development by Dong-A Socio Holdings and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tedizolid phosphate’s likelihood of approval (LoA) and phase transition for Abscess took place on 02 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 02 Aug 2022 increased Tedizolid phosphate’s LoA and PTSR for Cellulitis, increased LoA and PTSR for Erysipelas, and increased LoA and PTSR for Wounds.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tedizolid phosphate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tedizolid phosphate overview

Tedizolid phosphate (TR-701, DA-7218, Sivextro) is a phosphate prodrug, is converted to tedizolid in the presence of phosphatases. It is formulated as injectable powder solution and concentrate solution for intravenous route of administration and tablets, coated tablets and film coated tablets for oral route of administration. Tedizolid phosphate is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI), soft tissue infections (SSTI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, streptococcus agalactiae, streptococcus anginosus group (including streptococcus anginosus, streptococcus intermedius and streptococcus constellatus), and enterococccus faecalis.

The drug candidate is under development for the treatment of acute bacterial skin and skin structure infections including cellulitis, erysipelas, major cutaneous abscess, wound infection and gram-positive infections. It was also under development for the treatment of ventilator associated bacterial Pneumonia (VABP) and hospital acquired bacterial Pneumonia (HABP), cellulitis, erysipelas, bacteremia and and skin and soft tissue infections (SSTI),  complicated skin and skin structure infections and methicillin-resistant Staphylococcus aureus (MRSA) infections.

Dong-A Socio Holdings overview

Dong-A Socio Holdings, formerly Dong-A Pharmaceutical Co., Ltd, a subsidiary of Dong-A Socio Group offers business management services. It operates in various markets such as pharmaceuticals, food and beverages, logistics, IT, and materials. The group focuses on new business investments, APIs, OTC products, consumer goods, prescription drugs, development of biomedicines, and research and development of new innovative drugs. Its major products include quasi-drug, Bacchus; a cold medicine, Anti-inflammatory, Antipyretic, Analgesic Drug, namely, Panpyrin-T, Panpyrin Q; Morning Care; a tampon; contraceptive medicine such as Myvlar; among others. Dong-A Socio Holdings is headquartered in Seoul, South Korea.

Quick View Tedizolid phosphate LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Tedizolid phosphate
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Dermatology
  • Infectious Disease
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.